Carlyle Group Inc-The

SAIL’s 2025‑26 audited results reveal solid earnings growth, a 5.9% dividend yield above sector average, and a 3.2x P/E suggesting undervaluation, but board compliance gaps pose regulatory risk.

Explore Carlyle Group’s 2026 RSU grants to directors, their vesting terms, and the firm’s long‑term equity‑compensation strategy amid market volatility.

Explore how Carlyle’s board RSU awards may skew incentives, dilute shareholders, and raise governance questions—insights for investors and regulators.

Discover how Carlyle’s partnership with SEI unlocks private‑market access for retirement and wealth clients—boosting diversification, lowering fees, and streamlining compliance.

Barclays trims Carlyle target price yet keeps an overweight stance, citing rising revenue, healthy margins, and steady dividend support for long‑term value.

Discover how Carlyle’s $750 M stake in Nxtra Data and sale to QIA reshape India’s data‑center and coatings markets—insights on growth, regulation, and portfolio strategy.

Resonetics’ acquisition of Resolution Medical expands its end‑to‑end medical‑device manufacturing, boosting NPI, clean‑room capacity, and regulatory expertise to drive higher margins and investor returns.

Explore Carlyle Group’s Rule 144 offering: 500k shares on Nasdaq, boosting liquidity, institutional access, and private‑equity transparency for savvy investors.

Lincoln Minerals’ 2025 half‑year report reveals deep losses, new exploration gains, and bold green‑hydrogen and graphite partnerships—yet highlights cash burn, regulatory risks, and a going‑concern warning.

UBS cuts Carlyle’s target price to $65 amid tighter regulation and weaker PE deal flow, highlighting risks and a cautious outlook for the private‑equity firm.